Fig. 4: 89ZED88082A tumor uptake and volume from pre- to post-CART. | Nature Communications

Fig. 4: 89ZED88082A tumor uptake and volume from pre- to post-CART.

From: Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study

Fig. 4

a Estimated tumor uptake presented as geometric mean SUVpeak and volume over time (lines and dots) with 95% confidence bands, resulting from linear mixed models based on pre-CART (full cohort without EBV+ LBCL patients; n = 21 patients, 214 lesions) and post-CART days +2 (cohort 3; n = 8 patients, 79 lesions), +5 (cohort 2; n = 7 patients, 49 lesions) and +7 (cohort 1; n = 6 patients, 86 lesions) values. b Transversal views of 89ZED88082A PET/CT scans of para-iliac tumor lesions pre- and post-CART day +2. Arrows indicate regions of tumor tracer uptake, with corresponding CT images shown to the right. c Lesion-level correlation between pre- and post-CART day +2 (cohort 3; n = 8 patients, 79 lesions; exact P = 4.1 × 10−12) SUVpeak. The red line shows the linear mixed model regression fit with 95% confidence interval bands. P-value is based on a likelihood ratio test under maximum likelihood. d 89ZED88082A PET/CT transversal views of representative patient (cohort 3) with a mediastinal tumor lesion at pre-CART, post-CART days +2, +4, and +7. Adj., volume-adjusted. CART, chimeric antigen receptor T-cell therapy. LD, lymphodepletion. Source data are provided as a Source Data file.

Back to article page